ACIU Nov 2024 5.000 call
| Previous close | 1.2000 |
| Open | 1.2000 |
| Bid | 0.8500 |
| Ask | 1.4500 |
| Strike | 5.00 |
| Expiry date | 2024-11-15 |
| Day's range | 1.2000 - 1.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 717 |
GlobeNewswireAC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 Global Healthcare Conference, taking pl
Simply Wall St.Individual investors own 24% of AC Immune SA (NASDAQ:ACIU) shares but private equity firms control 30% of the company
Key Insights The considerable ownership by private equity firms in AC Immune indicates that they collectively have a...
- GlobeNewswire
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billionACI-24.060 ABATE Phase 2 trial on track to report Abeta-PET imaging results in Q2 2024, evaluating amyloid plaque reduction after 6 months of anti-Abeta active immunotherapyACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunothe
